Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382371824> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4382371824 endingPage "68" @default.
- W4382371824 startingPage "64" @default.
- W4382371824 abstract "Relevance: Cancer remains one of the leading causes of death in Kazakhstan, and CRISPR/Cas9 offers possible solutions to treat it. Clustered, regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) is a system bacteria use to cleave foreign in-vaders. This system has been considered promising for cancer therapeutics by allowing researchers to edit cancer cell genes.
 The system requires more trials, so it is essential to raise awareness of this technique for stu-dents and potential investors and highlight the current challenges that could be research opportuni-ties for researchers.
 The study aimed to analyze and provide up-to-date information from reputable scientific journals on the current use of the CRISPR/Cas9 system in cancer therapeutics for medical students and researchers. This research paper also highlights the challenges associated with implementing CRISPR/Cas9 in clinical settings for cancer therapeutics.
 Methods: The scientific literature and databases (PubMed and the Nature Journal) were searched and analyzed using the CRISPR/Cas9 system in cancer therapy.
 Results: The results of this research indicate that scientists should focus on improving the types and structure of the Cas protein as well as the delivery methods, including the non-viral deliv-ery methods (liposome-based particles, hybrid vectors, gold nanoparticles, and extracellular vesicles) to contribute to improving the current status of cancer therapeutics.
 Conclusion: CRISPR/Cas9 is an important technique that is still fraught with challenges and should be turned into research opportunities. The current challenges include the form and structure of the Cas nuclease, the types of engineering (in vivo vs. ex vivo), and the varieties of delivery methods. Each delivery method type has pros and cons and requires further research. In particular, future studies should focus on non-viral vectors, such as liposome-based particles, extracellular vesi-cles, hybrid vesicles, and gold nanoparticles." @default.
- W4382371824 created "2023-06-29" @default.
- W4382371824 creator A5077977422 @default.
- W4382371824 creator A5092349868 @default.
- W4382371824 date "2023-06-29" @default.
- W4382371824 modified "2023-10-01" @default.
- W4382371824 title "THE PROSPECTS AND CHALLENGES OF CRISPR/CAS9 GENE EDITING IN CANCER THERAPY: A LITERATURE REVIEW" @default.
- W4382371824 doi "https://doi.org/10.52532/2521-6414-2023-2-68-64-68" @default.
- W4382371824 hasPublicationYear "2023" @default.
- W4382371824 type Work @default.
- W4382371824 citedByCount "0" @default.
- W4382371824 crossrefType "journal-article" @default.
- W4382371824 hasAuthorship W4382371824A5077977422 @default.
- W4382371824 hasAuthorship W4382371824A5092349868 @default.
- W4382371824 hasBestOaLocation W43823718241 @default.
- W4382371824 hasConcept C104317684 @default.
- W4382371824 hasConcept C121608353 @default.
- W4382371824 hasConcept C132455925 @default.
- W4382371824 hasConcept C136764020 @default.
- W4382371824 hasConcept C144501496 @default.
- W4382371824 hasConcept C173853756 @default.
- W4382371824 hasConcept C2992929900 @default.
- W4382371824 hasConcept C41008148 @default.
- W4382371824 hasConcept C54355233 @default.
- W4382371824 hasConcept C70721500 @default.
- W4382371824 hasConcept C71924100 @default.
- W4382371824 hasConcept C86803240 @default.
- W4382371824 hasConcept C95444343 @default.
- W4382371824 hasConcept C98108389 @default.
- W4382371824 hasConceptScore W4382371824C104317684 @default.
- W4382371824 hasConceptScore W4382371824C121608353 @default.
- W4382371824 hasConceptScore W4382371824C132455925 @default.
- W4382371824 hasConceptScore W4382371824C136764020 @default.
- W4382371824 hasConceptScore W4382371824C144501496 @default.
- W4382371824 hasConceptScore W4382371824C173853756 @default.
- W4382371824 hasConceptScore W4382371824C2992929900 @default.
- W4382371824 hasConceptScore W4382371824C41008148 @default.
- W4382371824 hasConceptScore W4382371824C54355233 @default.
- W4382371824 hasConceptScore W4382371824C70721500 @default.
- W4382371824 hasConceptScore W4382371824C71924100 @default.
- W4382371824 hasConceptScore W4382371824C86803240 @default.
- W4382371824 hasConceptScore W4382371824C95444343 @default.
- W4382371824 hasConceptScore W4382371824C98108389 @default.
- W4382371824 hasIssue "2" @default.
- W4382371824 hasLocation W43823718241 @default.
- W4382371824 hasOpenAccess W4382371824 @default.
- W4382371824 hasPrimaryLocation W43823718241 @default.
- W4382371824 hasRelatedWork W213262456 @default.
- W4382371824 hasRelatedWork W2173737475 @default.
- W4382371824 hasRelatedWork W2516842346 @default.
- W4382371824 hasRelatedWork W2527347512 @default.
- W4382371824 hasRelatedWork W2770152187 @default.
- W4382371824 hasRelatedWork W2900771990 @default.
- W4382371824 hasRelatedWork W2943124855 @default.
- W4382371824 hasRelatedWork W2953290252 @default.
- W4382371824 hasRelatedWork W3030388918 @default.
- W4382371824 hasRelatedWork W3120857162 @default.
- W4382371824 hasVolume "68" @default.
- W4382371824 isParatext "false" @default.
- W4382371824 isRetracted "false" @default.
- W4382371824 workType "article" @default.